Qiagen N.V. (QGEN) Stock Competitors & Peer Comparison
See (QGEN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| QGEN | $41.51 | -1.14% | 8.6B | 17.30 | $2.40 | +6.34% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.73% |
| TMO | $527.05 | +0.45% | 195.9B | 22.76 | $23.16 | +0.34% |
| DHR | $199.05 | +1.57% | 140.9B | 24.94 | $7.98 | +0.73% |
| IDXX | $563.57 | +0.89% | 44.5B | 41.50 | $13.58 | N/A |
| NTRA | $269.95 | -4.22% | 38.7B | -169.78 | -$1.59 | N/A |
| A | $134.29 | +0.52% | 37.9B | 23.12 | $5.81 | +0.76% |
| IQV | $207.85 | -0.54% | 34.7B | 17.13 | $12.13 | N/A |
| ILMN | $190.20 | -1.84% | 28.8B | 37.81 | $5.03 | N/A |
| MTD | $1,296.17 | +0.63% | 26.2B | 29.78 | $43.51 | N/A |
Stock Comparison
QGEN vs DHR-PB Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, QGEN is priced at $41.51, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, QGEN's ROE is +0.11%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, QGEN is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check DHR-PB's competition here
QGEN vs TMO Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, TMO has a market cap of 195.9B. Regarding current trading prices, QGEN is priced at $41.51, while TMO trades at $527.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas TMO's P/E ratio is 22.76. In terms of profitability, QGEN's ROE is +0.11%, compared to TMO's ROE of +0.13%. Regarding short-term risk, QGEN is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check TMO's competition here
QGEN vs DHR Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, DHR has a market cap of 140.9B. Regarding current trading prices, QGEN is priced at $41.51, while DHR trades at $199.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas DHR's P/E ratio is 24.94. In terms of profitability, QGEN's ROE is +0.11%, compared to DHR's ROE of +0.07%. Regarding short-term risk, QGEN is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check DHR's competition here
QGEN vs IDXX Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, IDXX has a market cap of 44.5B. Regarding current trading prices, QGEN is priced at $41.51, while IDXX trades at $563.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas IDXX's P/E ratio is 41.50. In terms of profitability, QGEN's ROE is +0.11%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, QGEN is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check IDXX's competition here
QGEN vs NTRA Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NTRA has a market cap of 38.7B. Regarding current trading prices, QGEN is priced at $41.51, while NTRA trades at $269.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NTRA's P/E ratio is -169.78. In terms of profitability, QGEN's ROE is +0.11%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, QGEN is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NTRA's competition here
QGEN vs A Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, A has a market cap of 37.9B. Regarding current trading prices, QGEN is priced at $41.51, while A trades at $134.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas A's P/E ratio is 23.12. In terms of profitability, QGEN's ROE is +0.11%, compared to A's ROE of +0.21%. Regarding short-term risk, QGEN is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check A's competition here
QGEN vs IQV Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, IQV has a market cap of 34.7B. Regarding current trading prices, QGEN is priced at $41.51, while IQV trades at $207.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas IQV's P/E ratio is 17.13. In terms of profitability, QGEN's ROE is +0.11%, compared to IQV's ROE of +0.22%. Regarding short-term risk, QGEN is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check IQV's competition here
QGEN vs ILMN Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ILMN has a market cap of 28.8B. Regarding current trading prices, QGEN is priced at $41.51, while ILMN trades at $190.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ILMN's P/E ratio is 37.81. In terms of profitability, QGEN's ROE is +0.11%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, QGEN is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check ILMN's competition here
QGEN vs MTD Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MTD has a market cap of 26.2B. Regarding current trading prices, QGEN is priced at $41.51, while MTD trades at $1,296.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MTD's P/E ratio is 29.78. In terms of profitability, QGEN's ROE is +0.11%, compared to MTD's ROE of -6.10%. Regarding short-term risk, QGEN is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check MTD's competition here
QGEN vs WAT Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, WAT has a market cap of 24.5B. Regarding current trading prices, QGEN is priced at $41.51, while WAT trades at $376.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas WAT's P/E ratio is 27.72. In terms of profitability, QGEN's ROE is +0.11%, compared to WAT's ROE of +0.08%. Regarding short-term risk, QGEN is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check WAT's competition here
QGEN vs DGX Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, DGX has a market cap of 23B. Regarding current trading prices, QGEN is priced at $41.51, while DGX trades at $207.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas DGX's P/E ratio is 20.46. In terms of profitability, QGEN's ROE is +0.11%, compared to DGX's ROE of +0.14%. Regarding short-term risk, QGEN is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check DGX's competition here
QGEN vs LH Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, LH has a market cap of 22.8B. Regarding current trading prices, QGEN is priced at $41.51, while LH trades at $276.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas LH's P/E ratio is 16.47. In terms of profitability, QGEN's ROE is +0.11%, compared to LH's ROE of +0.11%. Regarding short-term risk, QGEN is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check LH's competition here
QGEN vs GH Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, GH has a market cap of 21.2B. Regarding current trading prices, QGEN is priced at $41.51, while GH trades at $160.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas GH's P/E ratio is -62.03. In terms of profitability, QGEN's ROE is +0.11%, compared to GH's ROE of +1.84%. Regarding short-term risk, QGEN is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check GH's competition here
QGEN vs EXAS Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, QGEN is priced at $41.51, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas EXAS's P/E ratio is -95.37. In terms of profitability, QGEN's ROE is +0.11%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, QGEN is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check EXAS's competition here
QGEN vs ILMNV Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, QGEN is priced at $41.51, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ILMNV's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to ILMNV's ROE of N/A. Regarding short-term risk, QGEN is more volatile compared to ILMNV. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check ILMNV's competition here
QGEN vs MEDP Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MEDP has a market cap of 15.4B. Regarding current trading prices, QGEN is priced at $41.51, while MEDP trades at $538.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MEDP's P/E ratio is 33.83. In terms of profitability, QGEN's ROE is +0.11%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, QGEN is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check MEDP's competition here
QGEN vs PKI Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, QGEN is priced at $41.51, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PKI's P/E ratio is 41.45. In terms of profitability, QGEN's ROE is +0.11%, compared to PKI's ROE of +0.03%. Regarding short-term risk, QGEN is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check PKI's competition here
QGEN vs ICLR Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ICLR has a market cap of 12.8B. Regarding current trading prices, QGEN is priced at $41.51, while ICLR trades at $167.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ICLR's P/E ratio is 13.68. In terms of profitability, QGEN's ROE is +0.11%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, QGEN is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check ICLR's competition here
QGEN vs RVTY Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, RVTY has a market cap of 12.5B. Regarding current trading prices, QGEN is priced at $41.51, while RVTY trades at $112.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas RVTY's P/E ratio is 21.93. In terms of profitability, QGEN's ROE is +0.11%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, QGEN is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check RVTY's competition here
QGEN vs CRL Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CRL has a market cap of 11.2B. Regarding current trading prices, QGEN is priced at $41.51, while CRL trades at $233.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CRL's P/E ratio is 23.34. In terms of profitability, QGEN's ROE is +0.11%, compared to CRL's ROE of -0.06%. Regarding short-term risk, QGEN is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check CRL's competition here
QGEN vs BLLN Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BLLN has a market cap of 5.8B. Regarding current trading prices, QGEN is priced at $41.51, while BLLN trades at $126.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BLLN's P/E ratio is 230.49. In terms of profitability, QGEN's ROE is +0.11%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, QGEN is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BLLN's competition here
QGEN vs TWST Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, TWST has a market cap of 5.6B. Regarding current trading prices, QGEN is priced at $41.51, while TWST trades at $90.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas TWST's P/E ratio is -44.43. In terms of profitability, QGEN's ROE is +0.11%, compared to TWST's ROE of -0.17%. Regarding short-term risk, QGEN is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check TWST's competition here
QGEN vs SHC Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, QGEN is priced at $41.51, while SHC trades at $18.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas SHC's P/E ratio is 20.47. In terms of profitability, QGEN's ROE is +0.11%, compared to SHC's ROE of +0.21%. Regarding short-term risk, QGEN is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check SHC's competition here
QGEN vs RDNT Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, RDNT has a market cap of 5.2B. Regarding current trading prices, QGEN is priced at $41.51, while RDNT trades at $65.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas RDNT's P/E ratio is 142.61. In terms of profitability, QGEN's ROE is +0.11%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, QGEN is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check RDNT's competition here
QGEN vs VCYT Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, VCYT has a market cap of 4.5B. Regarding current trading prices, QGEN is priced at $41.51, while VCYT trades at $56.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas VCYT's P/E ratio is 28.49. In terms of profitability, QGEN's ROE is +0.11%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, QGEN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check VCYT's competition here
QGEN vs SYNH Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, QGEN is priced at $41.51, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas SYNH's P/E ratio is 61.40. In terms of profitability, QGEN's ROE is +0.11%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, QGEN is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check SYNH's competition here
QGEN vs OLK Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, QGEN is priced at $41.51, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas OLK's P/E ratio is -96.59. In terms of profitability, QGEN's ROE is +0.11%, compared to OLK's ROE of -0.07%. Regarding short-term risk, QGEN is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check OLK's competition here
QGEN vs NEOG Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NEOG has a market cap of 2.1B. Regarding current trading prices, QGEN is priced at $41.51, while NEOG trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NEOG's P/E ratio is 34.36. In terms of profitability, QGEN's ROE is +0.11%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, QGEN is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NEOG's competition here
QGEN vs CDNA Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CDNA has a market cap of 1.5B. Regarding current trading prices, QGEN is priced at $41.51, while CDNA trades at $28.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CDNA's P/E ratio is 33.94. In terms of profitability, QGEN's ROE is +0.11%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, QGEN is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check CDNA's competition here
QGEN vs PSNL Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PSNL has a market cap of 1.2B. Regarding current trading prices, QGEN is priced at $41.51, while PSNL trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PSNL's P/E ratio is -13.79. In terms of profitability, QGEN's ROE is +0.11%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, QGEN is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check PSNL's competition here
QGEN vs CSTL Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CSTL has a market cap of 719.4M. Regarding current trading prices, QGEN is priced at $41.51, while CSTL trades at $23.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CSTL's P/E ratio is -53.91. In terms of profitability, QGEN's ROE is +0.11%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, QGEN is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check CSTL's competition here
QGEN vs FLGT Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, FLGT has a market cap of 583.6M. Regarding current trading prices, QGEN is priced at $41.51, while FLGT trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas FLGT's P/E ratio is 2055.00. In terms of profitability, QGEN's ROE is +0.11%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, QGEN is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check FLGT's competition here
QGEN vs GRALV Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, QGEN is priced at $41.51, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas GRALV's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to GRALV's ROE of N/A. Regarding short-term risk, QGEN is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check GRALV's competition here
QGEN vs MYGN Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MYGN has a market cap of 550.6M. Regarding current trading prices, QGEN is priced at $41.51, while MYGN trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MYGN's P/E ratio is -44.85. In terms of profitability, QGEN's ROE is +0.11%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, QGEN is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check MYGN's competition here
QGEN vs CO Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, QGEN is priced at $41.51, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CO's P/E ratio is 5.06. In terms of profitability, QGEN's ROE is +0.11%, compared to CO's ROE of +0.11%. Regarding short-term risk, QGEN is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check CO's competition here
QGEN vs NEO Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NEO has a market cap of 367.5M. Regarding current trading prices, QGEN is priced at $41.51, while NEO trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NEO's P/E ratio is 108.54. In terms of profitability, QGEN's ROE is +0.11%, compared to NEO's ROE of -0.12%. Regarding short-term risk, QGEN is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NEO's competition here
QGEN vs PRE Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PRE has a market cap of 303.6M. Regarding current trading prices, QGEN is priced at $41.51, while PRE trades at $17.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PRE's P/E ratio is -8.67. In terms of profitability, QGEN's ROE is +0.11%, compared to PRE's ROE of -0.47%. Regarding short-term risk, QGEN is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check PRE's competition here
QGEN vs FLDM Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, QGEN is priced at $41.51, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas FLDM's P/E ratio is -4.74. In terms of profitability, QGEN's ROE is +0.11%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, QGEN is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check FLDM's competition here
QGEN vs PRENW Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PRENW has a market cap of 247.2M. Regarding current trading prices, QGEN is priced at $41.51, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PRENW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, QGEN is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check PRENW's competition here
QGEN vs BDSX Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BDSX has a market cap of 174.4M. Regarding current trading prices, QGEN is priced at $41.51, while BDSX trades at $21.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BDSX's P/E ratio is -5.28. In terms of profitability, QGEN's ROE is +0.11%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, QGEN is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BDSX's competition here
QGEN vs IMDX Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, IMDX has a market cap of 136.4M. Regarding current trading prices, QGEN is priced at $41.51, while IMDX trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas IMDX's P/E ratio is -4.27. In terms of profitability, QGEN's ROE is +0.11%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, QGEN is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check IMDX's competition here
QGEN vs GTH Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, QGEN is priced at $41.51, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas GTH's P/E ratio is -1.11. In terms of profitability, QGEN's ROE is +0.11%, compared to GTH's ROE of -1.01%. Regarding short-term risk, QGEN is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check GTH's competition here
QGEN vs STIM Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, STIM has a market cap of 122.5M. Regarding current trading prices, QGEN is priced at $41.51, while STIM trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas STIM's P/E ratio is -3.26. In terms of profitability, QGEN's ROE is +0.11%, compared to STIM's ROE of -1.65%. Regarding short-term risk, QGEN is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check STIM's competition here
QGEN vs GENE Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, QGEN is priced at $41.51, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas GENE's P/E ratio is -38.25. In terms of profitability, QGEN's ROE is +0.11%, compared to GENE's ROE of -1.85%. Regarding short-term risk, QGEN is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check GENE's competition here
QGEN vs XGN Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, XGN has a market cap of 107.5M. Regarding current trading prices, QGEN is priced at $41.51, while XGN trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas XGN's P/E ratio is -6.01. In terms of profitability, QGEN's ROE is +0.11%, compared to XGN's ROE of -1.14%. Regarding short-term risk, QGEN is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check XGN's competition here
QGEN vs SERA Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, SERA has a market cap of 75.2M. Regarding current trading prices, QGEN is priced at $41.51, while SERA trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas SERA's P/E ratio is -3.03. In terms of profitability, QGEN's ROE is +0.11%, compared to SERA's ROE of -0.41%. Regarding short-term risk, QGEN is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check SERA's competition here
QGEN vs ATLN Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, QGEN is priced at $41.51, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ATLN's P/E ratio is -0.68. In terms of profitability, QGEN's ROE is +0.11%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, QGEN is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check ATLN's competition here
QGEN vs DRIO Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, DRIO has a market cap of 51.7M. Regarding current trading prices, QGEN is priced at $41.51, while DRIO trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas DRIO's P/E ratio is -1.21. In terms of profitability, QGEN's ROE is +0.11%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, QGEN is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check DRIO's competition here
QGEN vs STRR Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, STRR has a market cap of 43M. Regarding current trading prices, QGEN is priced at $41.51, while STRR trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas STRR's P/E ratio is -12.24. In terms of profitability, QGEN's ROE is +0.11%, compared to STRR's ROE of -0.14%. Regarding short-term risk, QGEN is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check STRR's competition here
QGEN vs PRPO Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PRPO has a market cap of 42.5M. Regarding current trading prices, QGEN is priced at $41.51, while PRPO trades at $23.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PRPO's P/E ratio is -91.54. In terms of profitability, QGEN's ROE is +0.11%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, QGEN is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check PRPO's competition here
QGEN vs STRRP Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, STRRP has a market cap of 40.4M. Regarding current trading prices, QGEN is priced at $41.51, while STRRP trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas STRRP's P/E ratio is -18.38. In terms of profitability, QGEN's ROE is +0.11%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, QGEN is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check STRRP's competition here
QGEN vs AKU Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, QGEN is priced at $41.51, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas AKU's P/E ratio is -0.13. In terms of profitability, QGEN's ROE is +0.11%, compared to AKU's ROE of -5.32%. Regarding short-term risk, QGEN is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check AKU's competition here
QGEN vs MDXH Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MDXH has a market cap of 24.8M. Regarding current trading prices, QGEN is priced at $41.51, while MDXH trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MDXH's P/E ratio is -1.27. In terms of profitability, QGEN's ROE is +0.11%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, QGEN is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check MDXH's competition here
QGEN vs QUCY Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, QUCY has a market cap of 17M. Regarding current trading prices, QGEN is priced at $41.51, while QUCY trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas QUCY's P/E ratio is -0.06. In terms of profitability, QGEN's ROE is +0.11%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, QGEN is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check QUCY's competition here
QGEN vs CEMI Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, QGEN is priced at $41.51, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CEMI's P/E ratio is -0.63. In terms of profitability, QGEN's ROE is +0.11%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, QGEN is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check CEMI's competition here
QGEN vs ENZ Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, QGEN is priced at $41.51, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ENZ's P/E ratio is -2.24. In terms of profitability, QGEN's ROE is +0.11%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, QGEN is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check ENZ's competition here
QGEN vs PMD Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, QGEN is priced at $41.51, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PMD's P/E ratio is -5.24. In terms of profitability, QGEN's ROE is +0.11%, compared to PMD's ROE of -0.32%. Regarding short-term risk, QGEN is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check PMD's competition here
QGEN vs ME Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, QGEN is priced at $41.51, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ME's P/E ratio is -0.03. In terms of profitability, QGEN's ROE is +0.11%, compared to ME's ROE of -42.03%. Regarding short-term risk, QGEN is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check ME's competition here
QGEN vs MYNZ Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, QGEN is priced at $41.51, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, QGEN's ROE is +0.11%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, QGEN is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check MYNZ's competition here
QGEN vs BNGO Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BNGO has a market cap of 13.8M. Regarding current trading prices, QGEN is priced at $41.51, while BNGO trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BNGO's P/E ratio is -0.27. In terms of profitability, QGEN's ROE is +0.11%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, QGEN is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BNGO's competition here
QGEN vs BNR Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BNR has a market cap of 11.9M. Regarding current trading prices, QGEN is priced at $41.51, while BNR trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BNR's P/E ratio is -13.78. In terms of profitability, QGEN's ROE is +0.11%, compared to BNR's ROE of -0.11%. Regarding short-term risk, QGEN is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BNR's competition here
QGEN vs CHEK Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, QGEN is priced at $41.51, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CHEK's P/E ratio is -0.43. In terms of profitability, QGEN's ROE is +0.11%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, QGEN is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check CHEK's competition here
QGEN vs CNTG Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, QGEN is priced at $41.51, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CNTG's P/E ratio is -0.23. In terms of profitability, QGEN's ROE is +0.11%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, QGEN is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check CNTG's competition here
QGEN vs APDN Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, QGEN is priced at $41.51, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas APDN's P/E ratio is -0.10. In terms of profitability, QGEN's ROE is +0.11%, compared to APDN's ROE of -6.53%. Regarding short-term risk, QGEN is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check APDN's competition here
QGEN vs MBAI Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MBAI has a market cap of 7.1M. Regarding current trading prices, QGEN is priced at $41.51, while MBAI trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MBAI's P/E ratio is 1.82. In terms of profitability, QGEN's ROE is +0.11%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, QGEN is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check MBAI's competition here
QGEN vs ADVB Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ADVB has a market cap of 5.8M. Regarding current trading prices, QGEN is priced at $41.51, while ADVB trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ADVB's P/E ratio is -48.45. In terms of profitability, QGEN's ROE is +0.11%, compared to ADVB's ROE of -0.65%. Regarding short-term risk, QGEN is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check ADVB's competition here
QGEN vs NVTA Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, QGEN is priced at $41.51, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NVTA's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.11%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, QGEN is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NVTA's competition here
QGEN vs LMDXW Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, QGEN is priced at $41.51, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.11%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, QGEN is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check LMDXW's competition here
QGEN vs LMDX Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, QGEN is priced at $41.51, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas LMDX's P/E ratio is -0.01. In terms of profitability, QGEN's ROE is +0.11%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, QGEN is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check LMDX's competition here
QGEN vs NDRA Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NDRA has a market cap of 4.2M. Regarding current trading prices, QGEN is priced at $41.51, while NDRA trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NDRA's P/E ratio is -0.72. In terms of profitability, QGEN's ROE is +0.11%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, QGEN is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NDRA's competition here
QGEN vs TRIB Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, TRIB has a market cap of 4M. Regarding current trading prices, QGEN is priced at $41.51, while TRIB trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas TRIB's P/E ratio is -0.10. In terms of profitability, QGEN's ROE is +0.11%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, QGEN is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check TRIB's competition here
QGEN vs BIAF Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BIAF has a market cap of 3.5M. Regarding current trading prices, QGEN is priced at $41.51, while BIAF trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BIAF's P/E ratio is -0.09. In terms of profitability, QGEN's ROE is +0.11%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, QGEN is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BIAF's competition here
QGEN vs DMTK Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, QGEN is priced at $41.51, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas DMTK's P/E ratio is -0.04. In terms of profitability, QGEN's ROE is +0.11%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, QGEN is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check DMTK's competition here
QGEN vs NOTV Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, QGEN is priced at $41.51, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NOTV's P/E ratio is -0.03. In terms of profitability, QGEN's ROE is +0.11%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, QGEN is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NOTV's competition here
QGEN vs SQL Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, QGEN is priced at $41.51, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas SQL's P/E ratio is -0.40. In terms of profitability, QGEN's ROE is +0.11%, compared to SQL's ROE of +38.02%. Regarding short-term risk, QGEN is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check SQL's competition here
QGEN vs AWH Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, QGEN is priced at $41.51, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas AWH's P/E ratio is -0.09. In terms of profitability, QGEN's ROE is +0.11%, compared to AWH's ROE of +2.03%. Regarding short-term risk, QGEN is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check AWH's competition here
QGEN vs INBS Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, INBS has a market cap of 1.4M. Regarding current trading prices, QGEN is priced at $41.51, while INBS trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas INBS's P/E ratio is -0.25. In terms of profitability, QGEN's ROE is +0.11%, compared to INBS's ROE of -1.74%. Regarding short-term risk, QGEN is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check INBS's competition here
QGEN vs HTGM Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, QGEN is priced at $41.51, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas HTGM's P/E ratio is -0.03. In terms of profitability, QGEN's ROE is +0.11%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, QGEN is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check HTGM's competition here
QGEN vs BIOC Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, QGEN is priced at $41.51, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BIOC's P/E ratio is -0.01. In terms of profitability, QGEN's ROE is +0.11%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, QGEN is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BIOC's competition here
QGEN vs ISPC Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, ISPC has a market cap of 337.4K. Regarding current trading prices, QGEN is priced at $41.51, while ISPC trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas ISPC's P/E ratio is -0.08. In terms of profitability, QGEN's ROE is +0.11%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, QGEN is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check ISPC's competition here
QGEN vs SQLLW Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, QGEN is priced at $41.51, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.11%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, QGEN is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check SQLLW's competition here
QGEN vs OCDX Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas OCDX's P/E ratio is -42.28. In terms of profitability, QGEN's ROE is +0.11%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, QGEN is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check OCDX's competition here
QGEN vs DHR-PA Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, QGEN's ROE is +0.11%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, QGEN is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check DHR-PA's competition here
QGEN vs BNGOW Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas BNGOW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, QGEN is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check BNGOW's competition here
QGEN vs PRXL Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas PRXL's P/E ratio is 43.49. In terms of profitability, QGEN's ROE is +0.11%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, QGEN is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for QGEN.Check PRXL's competition here
QGEN vs MEUSW Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas MEUSW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, QGEN is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check MEUSW's competition here
QGEN vs NDRAW Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas NDRAW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, QGEN is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check NDRAW's competition here
QGEN vs CHEKZ Comparison July 2026
QGEN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 8.6B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, QGEN is priced at $41.51, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 17.30, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.11%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, QGEN is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for QGEN.Check CHEKZ's competition here